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The Cardiothoracic Centre, Liverpool, United Kingdom
Extensive pancreatic damage causing loss of exocrine function is an early feature
in most CF patients, and results in steatorrhea and abnormal bowel function.
Although one of the aims of replacement oral enzyme therapy is to achieve a
normal bowel habit and stool formation, the amount of such therapy required to
achieve a satisfactory bowel habit varies between patients. The reasons for this are
complex. To investigate this further, we studied features of bowel habit in a cohort
of 63 CF patients (mean age 25.8 years [range 17 to 40], 33 males), attending our
adult unit and correlated them with replacement enzyme use.
All patients were interviewed whilst in a stable clinical state as outpatients. We
looked at bowel frequency per week, incidence of constipation, frequency of
diarrhoea per month, enzyme usage (iu lipase/kg body weight), use of laxatives/
antacids/iron supplementation, ﬂuid intake and ﬁbre intake, incidence of DIOS, and
the diagnosis of CFRD. Seven patients did not use enzymes, but of the remaining
56, the less well nourished used more enzymes (r = 0.368, P< 0.01). Although the
30 taking high strength enzymes had a greater daily intake than the remainder
(mean 10313 versus 4361 IUs lipase/kg, P< 0.001), nutritional status and bowel
function were similar. No differences were found when the patients were divided
into those with transmissible Pseudomonas strains [29], cepacia [10] or others [23].
Thus, we were unable to determine a relationship between the variables and
abnormality of bowel habit within our cross section of adult CF patients. This
conﬁrms that bowel dysfunction in CF is a complex condition, and is best managed
by skilled CF dieticians with individually tailored advice.
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Objective: To identify CF patients with a history of meconium ileus and to compare
long-term outcome of these patients with CF patients without meconium ileus.
Patients: 370 CF patients who were treated at the Munich CF centre in 2006, mean
age 17.1 years (range: 1 to 49), were classiﬁed with regard to a history of meconium
ileus.
Methods: Retrospective chart analysis regarding history of meconium ileus, liver
disease, CF related diabetes mellitus, age and lung function parameters (FEV-1%
predicted).
Results: We identiﬁed 58 patients with a history of meconium ileus (15.7%),
mean age 16.0±9 years (range: 1 to 33) who did not differ in age from patients
without meconium ileus (17.3±10;1 to 49). Mean FEV-1 in both groups was nearly
identical. In patients with meconium ileus it was 88.7±22.7 (median: 93.6; range: 17
to 134) compared to 87.6±27.2 (91.5; 21 to 148) in the patients without meconium
ileus (p = 0.73 in Wilcoxon rank sum test). The prevalence of diabetes mellitus was
comparable in both groups; 13.8% and 10.9% respectively (p = 0.52 in Chi square
test). CF associated liver disease however was more frequent in meconium ileus
patients (29.3%) compared to patients without meconium ileus (16.6%, p = 0.02 in
Chi square test).
Conclusion: The disadvantage of meconium ileus is associated with hospitalization
and possible acquisition of Pseudomonas aeruginosa or surgery. However, it
implicates the beneﬁt of an early CF diagnosis with consequent initiation of CF
therapy at an early stage. This explains the positive development of patients with
meconium ileus in our group of patients. A better outcome for CF patients without
meconium ileus could be achieved if CF diagnosis is established sooner, e. g. by
the implantation of neonatal screening.
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Liver disease is considered a serious complication of Cystic ﬁbrosis (CF) and can
limit the prognosis and quality of life of patients who are affected.
Objective: this study was designed to compare the liver course of children diag-
nosed with CF in infancy due to the presence of meconium ileus (MI) with children
diagnosed by way of a newborn screening programme (no MI) from February 1983
to July 2003 in two CF centers in France.
Material and Method: each MI child was pair-matched for age and genotype with
a CF patient without MI. The criteria used to deﬁne a diagnosis of CF-associated
liver disease were based on clinical, biochemical and ultrasound ﬁndings. Fifteen
patients with MI were enrolled.
Results: there were no signiﬁcant differences between two groups with regard to
weight, height, liver enzymes and distal intestinal obstruction syndrome.MI children
had a signiﬁcantly ﬁrst raised liver enzymes (p = 0.038). In the 15 patients with
a history of meconium ileus, the following hepatic abnormalities occured more
frequently than in the no MI group (p = 0.008):
– hepatomegaly
– persistently raised liver function tests and
– abnormal liver ultrasound scan.
Conclusion: Liver disease is a early complication of CF, whose detection should be
focused at the ﬁrst life decade in patients with history of meconium ileus. Preventive
treatment with ursodesoxycholic acid could be considered in patients with MI.
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Introduction: In Chile, there are 300 patients with cystic ﬁbrosis whose treatment is
ﬁnanced by the State. Most of them use pancreatic enzymes and its use is based on
clinical criteria and through indirect methods of measuring pancreatic sufﬁciency.
On the other hand, there is a small percentage of mutation detection in Chilean
patients.
Aim: To reclassify the patients with cystic ﬁbrosis that have a clinical diagnosis of
pancreatic insufﬁciency through the measurement of fecal elastase-1 and correlate
it with the genotype.
Methods: We studied 20 patients from 2 centers, 11 male and 9 female. Average
age 9 years. Fecal elastase was measured through ELISA (Elisa ScheBo Pancreatic
Elastase 1 Stool Test. The genotype was analyzed with a 33 mutation panel.
Results: The average age of diagnosis of Cystic Fibrosis was 29 months. The FE1
value ranged from 0 to 510 ug/gr, with an average of 128.3 ug/gr. In 15 patients
(75%) the value was <200 therefore had pancreatic insufﬁciency (PI), 12 of which
had 0, median value was 21.1 ug/gr. Five patients had normal values. All the patients
that had the F508 mutation had the FE1 in PI levels. 9 of which had 0 ug/gr and
one had 186.4 ug/gr. Two patients with the G542x mutation had opposing results,
one with 0 ug/gr and the other 491 ug/gr. One patient with R334W mutation had
pancreatic insufﬁciency (38.1 ug/gr).
Conclusion: In 75% of these Chilean patients with cystic ﬁbrosis and clinical PI
the diagnosis of PI is corroborated with low levels of fecal elastase.
The reclassiﬁcation of the patients according to the measurement of fecal elastase
could avoid the unnecessary use of pancreatic enzymes.
